Straits Times Index
3,223.63 -16.95 (-0.52%) Nikkei
26,894.27 +155.24 (+0.58%) Hang Seng
20,338.98 -378.26 (-1.83%) FTSE 100
7,389.98 +87.24 (+1.19%) BTC-USD
30,144.20 +821.67 (+2.80%) CMC Crypto 200
673.46 +0.09 (+0.01%)
Repare Therapeutics Inc. (RPTX)
After hours:
| Previous close | 8.57 |
| Open | 8.68 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 8.06 - 8.78 |
| 52-week range | 8.06 - 35.75 |
| Volume | |
| Avg. volume | 167,337 |
| Market cap | 354.006M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
CAMBRIDGE, Mass. & MONTREAL, May 09, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
- Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass. & MONTREAL, May 05, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.
- Business Wire
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
CAMBRIDGE, Mass. & MONTREAL, April 20, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306, a first-in-class small molecule candidate targeting PKMYT1, were published in Nature. SNIPRx®, Repare’s proprietary, genome-wide, CRISPR-based screening approach, was used to uncove
